|
시장보고서
상품코드
1673006
비용종 치료 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별Nasal Polyps Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
비용종 치료 세계 시장은 2025년에 36억 5,000만 달러, 2032년에는 61억 9,000만 달러에 달할 것으로 예상되며, 2025년부터 2032년까지 연평균 7.8%의 성장률을 보일 것으로 예상됩니다.
| 보고 범위 | 보고서 상세 내용 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 36억 5,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간(2025-2032년) CAGR | 7.80% | 2032년 가치 예측 | 61억 9,000만 달러 |
비용종 치료 세계 시장은 만성 부비동염의 전 세계 유병률 증가로 인해 괄목할 만한 성장세를 보이고 있습니다. 비용종은 비강 및 부비동 내벽에 발생하는 비암성 증식입니다. 보통 40-60세 성인에게 발병하며, 천식 환자에서 많이 발생합니다. 유전적 소인과 환경적 알레르겐 등의 요인이 발병에 관여할 수 있습니다. 비용종을 치료하지 않고 방치하면 코막힘, 후각 장애, 안면 압박감 및 통증을 유발할 수 있습니다. 기존 치료법으로는 약물요법, 수술, 경과 관찰 등이 있습니다. 하지만 부작용이 적은 신약의 등장으로 시장 성장이 기대되고 있습니다.
시장 역학
세계 비용종 치료 시장을 활성화시키는 주요 촉진요인으로는 만성 부비동염에 취약한 노령 인구 증가, 알레르기 유발 환경 오염 수준 증가, 최소 침습 수술의 채택 증가 등을 들 수 있습니다. 그러나 높은 수술 비용과 신흥국에서의 인식 부족이 시장 개척의 걸림돌로 작용하고 있습니다. 새로운 표적치료제 및 병용요법 개발에는 비즈니스 기회가 있습니다. 또한, 블록버스터 의약품의 특허 만료가 임박함에 따라 바이오시밀러 시장 진입의 여지도 있습니다.
본 조사의 주요 특징
세계의 비용종 치료 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
또한, 다양한 부문에 걸친 잠재적 수익 창출 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 고찰을 제공합니다.
기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 비용종 치료 시장의 주요 기업 프로파일을 제공합니다.
주요 기업으로는 사노피, 머크, 아스트라제네카, 리제네론, 노바티스, 옵티노스, GSK plc, 인터섹트 이비인후과(INTERSECT ENT, Inc.), 썬 파마슈티컬 인더스트리즈(Sun Pharmaceutical Industries Ltd.), Cipla, Mylan N.V., Genentech 등이 있습니다. Mylan N.V., Genentech 등이 있습니다.
이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
세계 비용종 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
- 역학
제4장 세계의 비용종 치료 시장, 약제 클래스별, 2020년-2032년(10억 달러)
- 코르티코스테로이드
- 인터류킨 억제제
- 항히스타민제
- 항생제
- 기타
제5장 세계의 비용종 치료 시장, 투여 경로별, 2020년-2032년(10억 달러)
- 비강
- 경구
- 비경구
제6장 세계의 비용종 치료 시장, 유통 채널별, 2020년-2032년(10억 달러)
- 병원 약국
- 소매 약국
- 온라인 약국
제7장 세계의 비용종 치료 시장, 지역별, 2020년-2032년, 금액(10억 달러)
- 북미
- 라틴아메리카
- 유럽
- 아시아태평양
- 중동
- 아프리카
제8장 경쟁 구도
- Sanofi
- Merck & Co., Inc.
- AstraZeneca
- Regeneron Pharmaceuticals Inc.
- Novartis AG
- Optinose
- GSK plc.
- INTERSECT ENT, Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla
- Mylan N.V.
- Genentech
제9장 애널리스트 추천 사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제10장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
- 출판사에 대해
Global Nasal Polyps Treatment Market is estimated to be valued at USD 3.65 Bn in 2025 and is expected to reach USD 6.19 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.65 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.80% | 2032 Value Projection: | USD 6.19 Bn |
The global nasal polyps treatment market has been witnessing significant growth due to the rising prevalence of chronic sinusitis worldwide. Nasal polyps are non-cancerous growths that develop in the lining of the nasal cavities or sinuses. They usually affect adults aged between 40 and 60 years and are more common in people with asthma. Factors such as genetic predisposition and environmental allergens can contribute to their development. If left untreated, nasal polyps can cause nasal obstruction, loss of smell, and facial pressure or pain. The existing treatment options include drug therapies, surgery, and watchful monitoring. However, the market is expected to witness growth in the emergence of new drugs with fewer side effects.
Market Dynamics:
The key drivers fueling the global nasal polyps treatment market include the growing geriatric population's susceptibility to chronic sinusitis, rising environmental pollution levels triggering allergies, and increasing adoption of minimally invasive surgeries. However, the high cost of surgery and lack of awareness in developing nations are restricting market growth. Opportunities lie in the development of novel targeted drug therapeutics and combinational therapies. The upcoming patent expiries of blockbuster drugs also allow scope for biosimilar market entries.
Key Features of the Study:
This report provides in-depth analysis of the global nasal polyps treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global nasal polyps treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Sanofi, Merck & Co., Inc., AstraZeneca, Regeneron Pharmaceuticals Inc., Novartis AG, Optinose, GSK plc., INTERSECT ENT, Inc., Sun Pharmaceutical Industries Ltd., Cipla, Mylan N.V., and Genentech
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global nasal polyps treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Market Segmentation
- By Drug Class Insights (Revenue, USD Bn, 2019 - 2032)
- Corticosteroids
- Interleukin Inhibitors
- Antihistamines
- Antibiotics
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2019 - 2032)
- Nasal
- Oral
- Parenteral
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2019 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Sanofi
- Merck & Co., Inc.
- AstraZeneca
- Regeneron Pharmaceuticals Inc.
- Novartis AG
- Optinose
- GSK plc.
- INTERSECT ENT, Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla
- Mylan N.V.
- Genentech
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Nasal Polyps Treatment Market, By Drug Class
- Global Nasal Polyps Treatment Market, By Route of Administration
- Global Nasal Polyps Treatment Market, By Distribution Channel
- Global Nasal Polyps Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
4. Global Nasal Polyps Treatment Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Interleukin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Nasal Polyps Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Nasal Polyps Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Nasal Polyps Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Optinose
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- INTERSECT ENT, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genentech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
